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Edited by Vladimir SkulachevAbstract The key transcription factor that regulates the cellu-
lar responses to hypoxia is hypoxia inducible factor-1 (HIF-1).
The signaling mechanisms that regulate the hypoxic activation
of HIF-1 are not fully understood. Our objective here was to test
whether AMP-activated kinase (AMPK) was an upstream regu-
lator of HIF-1. Our results show that AMPK is not required for
the hypoxic activation of HIF-1. Interestingly, the AMPK inhib-
itor, Compound C, inhibits the hypoxic activation of HIF-1 inde-
pendent of AMPK. Furthermore, we demonstrate that
Compound C functions as a repressor of HIF-1 by inhibiting res-
piration and suppressing mitochondrial generated ROS.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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species1. Introduction
Hypoxia is the reduction in normal oxygen tension and
occurs during acute and chronic vascular disease, pulmonary
disease and cancer. Hypoxia inducible factor 1 (HIF-1) is the
master transcription factor that regulates the cellular responses
to hypoxia [1]. HIF-1 is composed of two subunits, an oxygen-
sensitive HIF-1a subunit, and a constitutively expressed
HIF-1b subunit. HIF-1 activity is dependent on the availabil-
ity of the HIF-1a subunit. Under normal oxygen conditions
(21% O2), HIF-1a is targeted for ubiquitin-mediated degrada-
tion by an E3 ubiquitin ligase complex [2]. This process is
dependent on the hydroxylation of two proline residues by a
family of prolyl hydroxylase (PHD) enzymes [3–5]. Under hyp-
oxic conditions, hydroxylation is inhibited and HIF-1a is sta-
bilized [6]. To date the upstream regulators of HIF-1 are
poorly understood. The reactive oxygen species (ROS) gener-
ated within complex III of mitochondria during hypoxia has
been shown by multiple groups to be required and suﬃcient
to activate HIF-1 [6–10]. However, the direct targets of the
mitochondrial ROS or the upstream regulators of HIF-1 re-Abbreviations: HIF-1, hypoxia inducible factor 1; AMPK, AMP-
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mitochondria transduce hypoxic signals by regulating the
availability of oxygen for the PHDs to hydroxylate HIF-1a
[11,12].
AMP-activated kinase (AMPK) is a heterotrimeric serine/
threonine kinase consisting of a catalytic a subunit and two
regulatory b and c subunits [13–15]. AMPK is ubiquitously
expressed and functions as an intracellular fuel sensor by
maintaining energy balance. Hypoxia, ischemia, and ROS
are potent activators of AMPK [16–18]. Previous work has
genetically shown that AMPK is not necessary for HIF-1a
protein stability [18]. Yet, other reports have suggested that
Compound C prevents HIF-1 activation [19,20]. To resolve
this discrepancy and to investigate whether AMPK is an up-
stream regulator of HIF-1 we used both Compound C and
AMPKa null cells. Here we show that Compound C prevents
the hypoxic activation of HIF-1 by suppressing mitochondrial
generated ROS independent of AMPK.2. Materials and methods
2.1. Cell culture and reagents
AmpkaWT, Ampka1/, Ampka2/, and Ampka1/2/ mouse
embryonic ﬁbroblasts (MEFs), obtained from B. Viollet, were grown
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 4.5 g/l glucose,
L-glutamine, and sodium pyruvate, supplemented with 10% heat inac-
tivated fetal bovine serum (Gibco), 100 U/ml penicillin, 100 lg/ml
streptomycin, 0.25 lg/ml amphotericin B, and 20 mM HEPES. The
following reagents were used: Dimethyloxaloylglycine (DMOG)
(Frontier Scientiﬁc Inc.), Compound C (Calbiochem), and AICA-ribo-
side (AICAR) (Calbiochem).
2.2. Oxygen conditions
Hypoxic conditions (1.5% O2 and 5% CO2 balanced with N2) were
achieved in a humidiﬁed variable aerobic workstation (INVIVO O2,
BioTrace), which contains an oxygen sensor that continuously moni-
tors the chamber oxygen tension.
2.3. Immunoblot analysis
HIF-1a protein was analyzed in nuclear extracts as previously de-
scribed [21]. The anti-HIF-1a antibody (Cayman Chemical) was used
and an anti-POL II antibody (Santa Cruz Biotechnology Inc.) as the
loading control. For total cell lysates, the following antibodies were
used for immunoblotting: AMPKa, acetyl CoA carboxylase (ACC),
phospho-acetyl CoA carboxylase (Ser79) (all Cell Signaling Technol-
ogy Inc.), and an anti-a-tubulin antibody (Sigma–Aldrich Inc.) to con-
trol for loading. A representative blot is shown of three independent
experiments.
2.4. Transfections and reporter assays
Transfections were done using the TransIT Transfection reagent
(Mirus) according to manufacturer’s protocol. HIF-1 mediatedblished by Elsevier B.V. All rights reserved.
Fig. 1. Compound C inhibits hypoxic activation of HIF-1: (A) AMPK
activation assessed by phospho-ACC protein in WT cells exposed to
21% O2 (N), 1.5% O2 (H), 1 mM DMOG (D), or 0.5 mM AICAR
(A) ± 20 lMCompound C (C) for 30 min. Anti-ACC antibody used as
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ter gene construct, a pGL2 vector containing three hypoxia response
elements from the Pgk-1 gene upstream of ﬁreﬂy luciferase. Cells were
subjected to conditions for 16 h before lysates were collected. Lucifer-
ase values were determined using a dual-luciferase reporter assay kit
(Promega). Values for ﬁreﬂy luciferase were normalized to Renilla
luciferase under the control of the thymidine kinase promoter in the
pRLTK vector. The data presented are the result of triplicate analyses
and the error bars indicate standard error of the mean (S.E.M.).
2.5. Measurement of cell death
Cell death was measured using a cytotoxicity detection kit (Roche
Applied Science) according to manufacturer’s protocol. This kit is
based on the measurement of lactate dehydrogenase (LDH) that is re-
leased into the medium by damaged cells. Cell death is presented as
amount of LDH measured in the medium divided by the total LDH
released after treatment with 1% Triton X-100. All cell death results
are from four independent experiments and are represented as the
mean values ± standard error of the mean (S.E.M.).
2.6. Measurement of ROS
Intracellular ROS generation was assessed using 2 0,7 0-dichlorodihy-
droﬂuorescein diacetate (DCFH-DA) (Molecular Probes). ROS in the
cells cause oxidation of DCFH, yielding the ﬂuorescent product 2 0,7 0-
dichloroﬂuorescein (DCF). Cells were plated on Petri dishes and incu-
bated with DCFH-DA (10 lM) under various conditions. The media
was then removed, cells were lysed, centrifuged to remove debris,
and the ﬂuorescence in the supernatant was measured using a spectro-
ﬂuorometer (excitation, 500 nm; emission, 530 nm). Data were normal-
ized to values obtained from normoxic, untreated controls.
2.7. Oxygen consumption
Cellular O2 consumption rates were measured in aliquots of 1–
2 · 106 subconﬂuent cells removed from ﬂasks and studied in a mag-
netically stirred, water-jacketed (37 C) anaerobic respirometer ﬁtted
with a polarographic O2 electrode (Oxytherm system; Hansatech
Instruments). Oxygraph Plus software was used to determine oxygen
consumption rate. The data presented is the result of triplicate analyses
and the error bars indicate standard error of the mean (S.E.M.).loading control. (B) HIF-1a protein levels in WT cells exposed to 21%
O2 (N) ± 1 mMDMOG (D) or to 1.5% O2 (H) ± Compound C for 2 h.
Anti-POL II antibody used as loading control. (C) WT cells transfec-
ted with a HRE-Luciferase reporter gene construct and exposed to
21% O2 ± 1 mMDMOG or to 1.5% O2 ± Compound C for 16 h before
being harvested. Fireﬂy luciferase activity was normalized to renilla
luciferase activity and data reported as fold induction over 21% O2.3. Results
3.1. Compound C inhibits hypoxic activation of AMPK and
HIF-1
Compound C is known to function as an ATP-competitive
inhibitor of AMPK. To ﬁrst demonstrate that Compound C
inhibits the hypoxic activation of AMPK, cells were exposed
to 21% O2 (N), 1.5% O2 (H), DMOG (D), and AICAR
(A) ± Compound C. To assess AMPK activation, lysates were
immunoblotted using an antibody that recognizes the phos-
phorylation site (Ser79) on acetyl-CoA carboxylase (ACC), a
direct target of AMPK [14,22] (Fig. 1A). As expected, Com-
pound C inhibits both the hypoxic and AICAR induced acti-
vation of AMPK, whereas, the hypoxic mimetic DMOG
does not activate AMPK (Fig. 1A). DMOG is a PHD inhibitor
which serves as a hypoxic mimetic under normal oxygen con-
ditions, whereas, AICAR mimics AMP, thereby acting as an
activator of AMPK. To test the requirement of AMPK for
the hypoxic activation of HIF-1, cells were exposed to hypoxia
(1.5% O2) or normoxia (21% O2) in the presence or absence of
DMOG ± Compound C. Treatment with Compound C com-
pletely suppressed the stabilization of the HIF-1a protein un-
der hypoxia, whereas HIF-1a protein level was unaﬀected
with DMOG treatment (Fig. 1B). These results were further
conﬁrmed by examining HIF-1 activity using the HRE-Lucif-
erase assay (Fig. 1C). Hypoxia and DMOG increased HRE-
dependent luciferase induction in the untreated cells(Fig. 1C). In contrast, cells treated with Compound C dis-
played a marked attenuation of luciferase induction under hy-
poxia but not in the presence of DMOG during normoxia
(Fig. 1C).
3.2. AMPK is not required for hypoxic activation of HIF-1
To genetically examine the requirement of AMPK for the
hypoxic activation of HIF-1, the double knockout cells for
AMPKa1 and AMPKa2, as well as, the individual null cells
for AMPKa1 and AMPKa2 were used. First, Ampka WT
and the Ampka1/2/ cells were exposed to hypoxia (1.5%
O2) or normoxia (21% O2) in the presence or absence of
DMOG. Interestingly, the loss of both AMPKa1 and AMP-
Ka2 did not aﬀect HIF-1a protein levels under hypoxia
(Fig. 2A). Moreover, Ampka1/ and Ampka2/ cells also
displayed no diﬀerences in HIF-1a protein levels when sub-
jected to hypoxia (Fig. 2B). Lastly, the HRE-Luciferase assay
displayed no diﬀerence between the Ampka WT and the
Ampka1/2/ cells under hypoxia (Fig. 2C), providing ge-
netic evidence that the hypoxic activation of HIF-1 is not
dependent on AMPK, coinciding with data published by
Laderoute et al. [18].
Fig. 2. AMPK is not required for hypoxic activation of HIF-1: (A)
HIF-1a protein levels in AMPKa WT and AMPKa1/a2/ cells
exposed to 21% O2 (N) ± 1 mM DMOG (D) or to 1.5% O2 (H) for 2 h.
Anti-POL II antibody used as loading control. (B)HIF-1a protein levels
in AMPKa1/ and AMPKa2/ cells exposed to 21% O2 (N) ± 1 mM
DMOG (D) or to 1.5% O2 (H) for 2 h. Anti-POL II antibody used as
loading control. (C) AMPKa WT and AMPKa1/a2/ cells trans-
fected with a HRE-Luciferase reporter gene construct and exposed to
21% O2 ± 1 mMDMOG or to 1.5% O2 for 16 h before being harvested.
Fireﬂy luciferase activity was normalized to renilla luciferase activity
and data reported as fold induction over 21% O2 AMPKa WT.
Fig. 3. Compound C inhibits hypoxic activation of HIF-1 in AMPKa
null cells: (A) AMPKa protein levels in AMPKaWT and AMPKa1/
a2/ cells. Anti-tubulin antibody used as loading control. (B) HIF-1a
protein levels in AMPKa WT and AMPKa1/a2/ cells exposed to
21% O2 (N) ± 1 mMDMOG (D) or to 1.5% O2 (H) ± Compound C for
2 h.Anti-POL II antibody used as loading control. (C)AMPKaWTand
AMPKa1/a2/ cells transfected with a HRE-Luciferase reporter
gene construct and exposed to 21% O2 ± 1 mM DMOG or to 1.5%
O2 ± 20 lM Compound C for 16 h before being harvested. Fireﬂy
luciferase activity was normalized to renilla luciferase activity and data
reported as fold induction over 21% O2 AMPKaWT.
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To resolve the discrepancy above, a HRE-Luciferase assay
was used to examine HIF-1 activity in the Ampka1/2/ in
the presence or absence of Compound C. As shown by immu-
noblotting, these cells are null for AMPKa (Fig. 3A). Similar
to Fig. 2A, hypoxic and DMOG treated Ampka1/2/
cells stabilized the HIF-1a protein (Fig. 3B). Whereas, treat-
ment with Compound C in the hypoxic Ampka1/2/ cells
inhibited HIF-1a protein stability (Fig. 3B). Furthermore,
Compound C had no aﬀect on DMOG treated Ampka1/
2/ cells (Fig. 3B). Conﬁrming the results shown in
Fig. 1C, WT cells treated with Compound C displayed a
severe reduction in HRE- Luciferase expression when
exposed to hypoxia in comparison to untreated WT cells
(Fig. 3C). Interestingly, hypoxic untreated Ampka1/2/
cells showed an increase in HRE-Luciferase expression,
whereas the hypoxic Ampka1/2/ cells treated with Com-
pound C displayed no induction of HRE-Luciferase under
hypoxia (Fig. 3C).3.4. Compound C inhibits mitochondrial function
A functional electron transport chain is required for hypoxic
activation of HIF-1. To examine if Compound C prevented
HIF-1 activity by inhibiting oxidative phosphorylation, cells
adapted to either glucose or galactose were treated with Com-
pound C for 24, 48, and 72 h and cell death was measured by
LDH release (Fig. 4A). Glucose adapted cells treated with
Compound C displayed less than 20% cell death at all time
points (Fig. 4A). Untreated galactose adapted cells, which rely
entirely on oxidative phosphorylation for survival, showed
similar percentages of cell death. Galactose adapted cells dis-
play higher oxygen consumption than glucose adapted cells
(14.4 nmol/min/million cells vs. 6.34 nmol/min/million cells).
Interestingly, galactose adapted cells that were treated with
Compound C exhibited near 40% cell death at 48 h and greater
than 90% cell death at 72 h (Fig. 4A). Therefore, Compound C
induces cell death in the presence of galactose. To further
examine Compound C’s eﬀect on respiration, oxygen
Fig. 4. Compound C inhibits oxygen consumption and ROS generation: (A) WT cells adapted to glucose or galactose ± 20 lMCompound C for 24,
48, and 72 h and cell death assessed by LDH release. (B and C) Oxygen consumption of WT cells with 20 lMCompound C or DMSO control in the
presence of FCCP. N = 3 means ± S.D. (D) ROS determined by incubating WT cells with DCFH-DA (10 lM) exposed to 21% O2 1.5% O2 ± 20 lM
Compound C, or to 1 mM DMOG ± 20 lM Compound C for 30 min. N = 4 means ± S.D.
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sence of Compound C (Figs. 4B and C). In fact, Compound C
inhibits respiration. The likely mechanism is electron transport
inhibition since compound C inhibits respiration in the pres-
ence of the uncoupler FCCP (10 lM). Previous studies have
demonstrated that hypoxia increases the generation of oxi-
dants during the ubiquinione cycle within complex III of the
mitochondria and these oxidants are required and suﬃcient
for HIF-1 activation [6–10]. Indeed, ROS is generated by hy-
poxia, as detected by the oxidation of the 2 0,7 0-dichlorodihy-
droﬂuorescein (DCFH) dye and Compound C suppresses
mitochondrial generated oxidants in response to hypoxia
(Fig. 4D). Treatment with DMOG had no eﬀect on ROS gen-
eration (Fig. 4D).4. Discussion
Compound C is well established and a potent inhibitor of
AMPK. Hypoxia is known to activate AMPK. Consistent with
previous reports Compound C prevents hypoxia activation of
AMPK. Compound C also inhibits the hypoxic activation of
HIF-1, correlating with other reports that have suggested
that AMPK is critical for HIF-1 activity by using CompoundC under hypoxic conditions or exposure to the carcinogenic
metal vanadate [19,20]. In contrast to the Compound C data,
cells deﬁcient in AMPKa1 and a2 are able to still activate
HIF-1 during hypoxia. The novel ﬁnding in the present study
is that Compound C still prevents the hypoxic activation of
HIF-1 in cells deﬁcient in both AMPKa1 and a2. This indi-
cates that Compound C can eﬀectively suppress the hypoxic
activation of HIF-1 independently of AMPK. Therefore,
Compound C can be added to the list of known AMPK mod-
ulators, including AICAR and Metformin, which have oﬀ tar-
get eﬀects. In addition, DN-AMPK adenoviruses have been
shown to inhibit the activation of HIF-1, although these ap-
proaches also have oﬀ target eﬀects [19,20]. Here we used
AMPKa null cells, providing genetics in order to study the
requirement of AMPK for the hypoxic activation of HIF-1.
Previous studies have demonstrated that a functional elec-
tron transport chain is necessary to produce an increase in
ROS that subsequently stabilize HIF-1a in response to hypox-
ia [6,7,9,10]. Indeed we found that Compound C is also a mito-
chondrial inhibitor. The actual mitochondrial origin of ROS
suppressed by Compound C remains unclear. Bell and col-
leagues have recently published that the ROS generated by
the Q0 site of complex III is required for hypoxic signaling
[6]. Therefore, Compound C may be acting directly or indi-
B.M. Emerling et al. / FEBS Letters 581 (2007) 5727–5731 5731rectly at this site in order to suppress the hypoxic activation of
HIF-1. Additionally, Compound C is part of a pyrazolo-
pyrimidine class of protein kinase inhibitors, therefore it is
possible that this compound is also inhibiting other kinase sig-
naling pathways that regulate HIF-1 [23]. For example, p38a
MAPK is required for the hypoxic activation of HIF-1 [21].
Compound C may inﬂuence the p38 MAPK pathway, as well
as, inhibit mitochondrial respiration in order to suppress hyp-
oxic signaling. Cells treated with Compound C failed to sur-
vive in media containing galactose instead of glucose. Cells
adapted to galactose rely on oxidative phosphorylation for
survival. Compound C inhibited respiration as measured by
oxygen consumption. Furthermore, Compound C suppresses
the hypoxia generated increase in ROS, thus providing a mech-
anistic explanation for why Compound C is eﬀective in sup-
pressing the hypoxic activation of HIF-1. In conclusion, this
study demonstrates that Compound C is not only an inhibitor
of AMPK, but it inhibits the hypoxic activation of HIF-1 by
suppressing mitochondrial generated ROS. These results fur-
ther highlight the importance of mitochondria as a major reg-
ulator of the hypoxic activation of HIF-1.
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